Long/short equity, research analyst, biotech, healthcare

Hemispherx Biopharma: A Voice Of Reason Amid The Din

The clock is quickly ticking down towards Hemispherx Biopharma's (NYSEMKT:HEB) Food and Drug Administration (FDA) December 20th meeting with the Arthritis Advisory Committee (NASDAQ:AAC) to discuss Ampligen's New Drug Application (NDA) for Chronic Fatigue Syndrome (CFS). As previously announced, the Prescription Drug User Fee Act (PDUFA) review goal for Ampligen is February 2nd, 2013.

The bulls and bears are thus having a vociferous argument over whether or not Ampligen will finally be approved this time around. With about a million people affected by CFS in the U.S. alone, an FDA approval of Ampligen could thus result in one of the more impressive share price appreciations in recent history. Specifically, HEB's current market cap of $116M ...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details